Apyx Medical Corporation

NasdaqGS:APYX Rapport sur les actions

Capitalisation boursière : US$45.7m

La traduction de cette page est expérimentale et en cours de développement. N'hésitez pas à vos !

Apyx Medical Gestion

Gestion contrôle des critères 3/4

Le PDG Apyx Medical's est Charlie Goodwin, nommé en Dec2017, a un mandat de 6.67 ans. La rémunération annuelle totale est $ 1.26M, composée du salaire de 38.2% et des bonus 61.8%, y compris les actions et options de la société. détient directement 0.26% des actions de la société, d'une valeur de $ 118.80K. La durée moyenne de mandat de l'équipe de direction et du conseil d'administration est respectivement 5.6 ans et 6.5 ans.

Informations clés

Charlie Goodwin

Directeur général

US$1.3m

Rémunération totale

Pourcentage du salaire du PDG38.2%
Durée du mandat du directeur général6.7yrs
Propriété du PDG0.3%
Durée moyenne d'occupation des postes de direction5.6yrs
Durée moyenne du mandat des membres du conseil d'administration6.5yrs

Mises à jour récentes de la gestion

We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed

Aug 01
We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed

Recent updates

Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

Aug 07
Apyx Medical Corporation (NASDAQ:APYX) Stock's 25% Dive Might Signal An Opportunity But It Requires Some Scrutiny

We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed

Aug 01
We Discuss Why Apyx Medical Corporation's (NASDAQ:APYX) CEO Compensation May Be Closely Reviewed

Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?

Jun 19
Is Apyx Medical (NASDAQ:APYX) Using Debt In A Risky Way?

Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive

Apr 18
Revenues Working Against Apyx Medical Corporation's (NASDAQ:APYX) Share Price Following 25% Dive

Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates

Mar 26
Apyx Medical Corporation (NASDAQ:APYX) Analysts Just Slashed This Year's Estimates

Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)

Feb 16
Take Care Before Diving Into The Deep End On Apyx Medical Corporation (NASDAQ:APYX)

Is Apyx Medical (NASDAQ:APYX) A Risky Investment?

Sep 14
Is Apyx Medical (NASDAQ:APYX) A Risky Investment?

Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?

Jun 07
Does Apyx Medical (NASDAQ:APYX) Have A Healthy Balance Sheet?

Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically

Mar 21
Forecast: Analysts Think Apyx Medical Corporation's (NASDAQ:APYX) Business Prospects Have Improved Drastically

Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation

Dec 14
Here's Why We're Watching Apyx Medical's (NASDAQ:APYX) Cash Burn Situation

We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate

Aug 30
We're Not Very Worried About Apyx Medical's (NASDAQ:APYX) Cash Burn Rate

Apyx Medical GAAP EPS of -$0.16 beats by $0.03, revenue of $10.3M misses by $0.26M

Aug 11

Apyx Medical gets FDA nod for Renuvion's use in improving loose skin on neck, chin

Jul 18

Companies Like Apyx Medical (NASDAQ:APYX) Are In A Position To Invest In Growth

May 26
Companies Like Apyx Medical (NASDAQ:APYX) Are In A Position To Invest In Growth

Analyse de la rémunération des PDG

Comment la rémunération de Charlie Goodwin a-t-elle évolué par rapport aux bénéfices de Apyx Medical?
DateRémunération totaleSalaireBénéfices de l'entreprise
Jun 30 2024n/an/a

-US$28m

Mar 31 2024n/an/a

-US$23m

Dec 31 2023US$1mUS$483k

-US$19m

Sep 30 2023n/an/a

-US$15m

Jun 30 2023n/an/a

-US$16m

Mar 31 2023n/an/a

-US$21m

Dec 31 2022US$2mUS$483k

-US$23m

Sep 30 2022n/an/a

-US$19m

Jun 30 2022n/an/a

-US$18m

Mar 31 2022n/an/a

-US$16m

Dec 31 2021US$2mUS$450k

-US$15m

Sep 30 2021n/an/a

-US$15m

Jun 30 2021n/an/a

-US$14m

Mar 31 2021n/an/a

-US$15m

Dec 31 2020US$2mUS$450k

-US$12m

Sep 30 2020n/an/a

-US$16m

Jun 30 2020n/an/a

-US$16m

Mar 31 2020n/an/a

-US$16m

Dec 31 2019US$2mUS$450k

-US$20m

Sep 30 2019n/an/a

-US$18m

Jun 30 2019n/an/a

-US$15m

Mar 31 2019n/an/a

-US$14m

Dec 31 2018US$1mUS$400k

-US$11m

Sep 30 2018n/an/a

-US$10m

Jun 30 2018n/an/a

-US$12m

Mar 31 2018n/an/a

-US$15m

Dec 31 2017US$2mUS$15k

-US$14m

Rémunération vs marché: La rémunération totale de Charlie ($USD 1.26M ) est supérieure à la moyenne des entreprises de taille similaire sur le marché US ($USD 681.57K ).

Rémunération et revenus: La rémunération de Charlie a été cohérente avec les performances de l'entreprise au cours de l'année écoulée.


PDG

Charlie Goodwin (57 yo)

6.7yrs

Titularisation

US$1,261,470

Compensation

Mr. Charles D. Goodwin II, also known as Charlie, has been Chief Executive Officer and Director of Apyx Medical Corporation (formerly known as Bovie Medical Corporation) since December 15, 2017 and serves...


Équipe de direction

NomPositionTitularisationCompensationPropriété
Charles Goodwin
President6.7yrsUS$1.26m0.26%
$ 118.8k
Matthew Hill
CFO, Treasurer & Secretaryless than a yearUS$445.95k0.023%
$ 10.3k
Moshe Citronowicz
Senior Vice President12.6yrsUS$538.31k1.32%
$ 602.6k
Todd Hornsby
Executive Vice President5.6yrsUS$746.27k0%
$ 0
Stavros Vizirgianakis
Executive Chairmanless than a yearpas de données5.04%
$ 2.3m

5.6yrs

Durée moyenne de l'emploi

55yo

Âge moyen

Gestion expérimentée: L'équipe de direction de APYX est chevronnée et expérimentée (ancienneté moyenne 5.6 ans).


Membres du conseil d'administration

NomPositionTitularisationCompensationPropriété
Charles Goodwin
President6.7yrsUS$1.26m0.26%
$ 118.8k
Stavros Vizirgianakis
Executive Chairmanless than a yearpas de données5.04%
$ 2.3m
Michael Geraghty
Independent Director13.4yrsUS$114.06k0.079%
$ 36.3k
Lawrence Waldman
Lead Independent Director13.4yrsUS$162.56k0.12%
$ 56.6k
Brian Kinney
Member of Medical Advisory Board5.1yrspas de donnéespas de données
Gregory Konesky
Member of Scientific Advisory Boardno dataUS$9.30kpas de données
Yuval Carmel
Member of Scientific Advisory Boardno datapas de donnéespas de données
John C. Andres
Independent Vice-Chairman of the Board10.1yrsUS$144.06k0%
$ 0
Minnie Baylor-Henry
Independent Director5yrsUS$116.56k0%
$ 0
Craig Swandal
Independent Director6.4yrsUS$106.56k0.22%
$ 101.9k
Dennis Chi
Member of Medical Advisory Board7.6yrspas de donnéespas de données
Diane Duncan
Member of Medical Advisory Board6.3yrspas de donnéespas de données

6.5yrs

Durée moyenne de l'emploi

68yo

Âge moyen

Conseil d'administration expérimenté: Les membres du conseil d'administration de APYX sont considérés comme expérimentés (ancienneté moyenne 6.5 ans).